UAB-developed viral immunotherapy for pediatric brain tumors shows promise | News

A second-generation virus called M032 was developed by Markert and associates Yancey Gillespie, professor of neurosurgery, and Dr. Richard Whitley, professor of childhood infectious diseases, and is in clinical trials on UAB in adults with glioblastoma. UAB researcher Dr. Renee Chambers uses M032 in a study of brain tumors in dogs, which can develop tumors very similar to those in humans.

In the current study with G207, 11 out of 12 patients responded to treatment. The overall survival rate was more than double the typical rate for children with high-grade glioma. Approximately 36% of patients have survived more than 18 months to date, exceeding the medial overall survival for newly diagnosed patients with high-grade glioma.

Friedman’s team reports that G207 alone or in combination with radiation therapy was well tolerated, with no serious side effects attributed to the treatment.

“More studies are needed; but so far, viral immunotherapy with several viruses, including the herpes virus, has shown promising results for the treatment of high-quality brain tumors in both adults and children, ”said Friedman. “We also have an ongoing clinical trial to test the safety of G207 when administered into the cerebellum, an area of ​​the brain that has not been previously tested in adults or children, but is the most common site for its onset. Of pediatric tumors. “

Comments are closed.